Published in
Springer, Cancer Immunology, Immunotherapy, 12(69), p. 2589-2598, 2020
DOI: 10.1007/s00262-020-02618-4
Links
Tools
A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases
Journal article published in 2020 by
Yanina Jansen 
,
Vibeke Kruse,
Jurgen Corthals,
Kelly Schats,
Pieter-Jan van Dam,
Teofila Seremet ,
Carlo Heirman,
Lieve Brochez,
Mark Kockx,
Kris Thielemans,
Bart Neyns
,
Vibeke Kruse,
Jurgen Corthals,
Kelly Schats,
Pieter-Jan van Dam,
Teofila Seremet ,
Carlo Heirman,
Lieve Brochez,
Mark Kockx,
Kris Thielemans,
Bart Neyns
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 